CAJ | 학술논문

目的：分析回生口服液联合长春瑞滨＋顺铂（NP）方案化疗对肺癌患者免疫功能的影响。方法选取本院2011年8月至2013年8月住院治疗的非小细胞肺癌（NSCLC）患者100例，随机分为试验组和对照组，每组各50例。对照组患者予以NP方案化疗，试验组患者在对照组基础上加服回生口服液。治疗2个疗程后对比两组患者T细胞亚群、自然杀伤（NK）细胞及细胞因子水平。结果两组患者治疗2个疗程后CD3、CD4、CD8、NK细胞水平均显著高于治疗前（P＜0.05）；试验组患者治疗2个疗程后CD3、CD4、CD8、CD4/CD8及NK细胞水平均显著高于对照组，差异具有显著性（P＜0.05）；两组患者治疗2个疗程后CD8+CD28-T细胞、CD4+CD152+T细胞、CD8+CD152+T细胞水平均显著低于治疗前，而CD4+CD28+T细胞水平高于治疗前，差异具有显著性（P＜0.01）；试验组患者治疗2个疗程后CD8+CD28-T细胞、CD4+CD152+T细胞、CD8+CD152+T细胞水平均显著低于对照组，而CD4+CD28+T细胞水平高于对照组，差异具有显著性（P＜0.01）；两组患者治疗2个疗程后白细胞介素（IL）-6和IL-18水平显著高于治疗前，血清可溶性脂肪酸合成酶（sFas）水平显著低于治疗前，差异具有显著性（P＜0.01）；试验组患者治疗2个疗程后IL-6和IL-18水平显著高于对照组，sFas水平显著低于对照组，差异具有显著性（P＜0.01）。结论回生口服液联合NP方案可显著改善NSCLC患者免疫功能，同时抑制肿瘤细胞的凋亡抵抗，值得临床推广应用。
목적：분석회생구복액연합장춘서빈＋순박（NP）방안화료대폐암환자면역공능적영향。방법선취본원2011년8월지2013년8월주원치료적비소세포폐암（NSCLC）환자100례，수궤분위시험조화대조조，매조각50례。대조조환자여이NP방안화료，시험조환자재대조조기출상가복회생구복액。치료2개료정후대비량조환자T세포아군、자연살상（NK）세포급세포인자수평。결과량조환자치료2개료정후CD3、CD4、CD8、NK세포수평균현저고우치료전（P＜0.05）；시험조환자치료2개료정후CD3、CD4、CD8、CD4/CD8급NK세포수평균현저고우대조조，차이구유현저성（P＜0.05）；량조환자치료2개료정후CD8+CD28-T세포、CD4+CD152+T세포、CD8+CD152+T세포수평균현저저우치료전，이CD4+CD28+T세포수평고우치료전，차이구유현저성（P＜0.01）；시험조환자치료2개료정후CD8+CD28-T세포、CD4+CD152+T세포、CD8+CD152+T세포수평균현저저우대조조，이CD4+CD28+T세포수평고우대조조，차이구유현저성（P＜0.01）；량조환자치료2개료정후백세포개소（IL）-6화IL-18수평현저고우치료전，혈청가용성지방산합성매（sFas）수평현저저우치료전，차이구유현저성（P＜0.01）；시험조환자치료2개료정후IL-6화IL-18수평현저고우대조조，sFas수평현저저우대조조，차이구유현저성（P＜0.01）。결론회생구복액연합NP방안가현저개선NSCLC환자면역공능，동시억제종류세포적조망저항，치득림상추엄응용。
Objective To analyze huisheng oral liquid combined with vinorelbine+cisplatin (NP) chemotherapy on immune function in patients with lung cancer. Method 100 patients with non-small cell lung cancer (NSCLC) hospitalized from August 2011 to August 2013 were randomly divided into experimental group and control group, 50 cases in each group. Control group were given NP chemotherapy, experimental group were added with regenerative oral. After two courses of treatment, T-cell subsets, natural killer (NK) cells and cytokine levels were compared in two groups of patients. Result After two courses of treatment, the levels of CD3, CD4, CD8, NK cell were signiifcantly higher than before treatment (P < 0.05), the levels of CD3, CD4, CD8, CD4/CD8 and the ratio of NK cells in experiment group were signiifcantly higher than control group, the difference was signiifcant (P < 0.05);after two courses of treatment, the levels of CD8+CD28-T cells, CD4+CD152+T cells, CD8+CD152+T cells of two groups of patients were signiifcantly lower than before treatment, the level of CD4+CD28+T cells was higher than before treatment, the difference was significant difference (P < 0.01);after two courses of treatment, the levels of CD8+CD28-T cells, CD4+CD152+T cells, CD8+CD152+T cells in experimenr group were signiifcantly lower than control group, CD4+CD28+T cells was higher than control group, the difference was signiifcant (P<0.01);after two courses of treatment, two groups of patients IL-6 and IL-18 levels were signiifcantly higher than that before treament, the serum levels of sFas levels were signiifcantly lower than that before treatment, the difference was signiifcant (P<0.01), IL-6 and IL-18 levels in experiment group were signiifcantly higher than control group, sFas level was signiifcantly lower than control group, the difference was signiifcant (P<0.01). Conclusion Huisheng oral liquid combined with NP scheme can signiifcantly improve the level of immunity in patients with NSCLC, simultaneous inhibition of tumor cell apoptosis resistance, which is worthy of clinical application.